Stock Analiz

Scilex Holding Co SCLX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$1.43Market cap $12M
Open the interactive analysis →

Scilex Holding Co (SCLX) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to June 30, 2026 it had revenue of $32M and net income of -$465M, a net margin of -1469.8%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -106%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 28% below the current price.

About Scilex Holding Co

Scilex Holding Co is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $24M in 2020 to $30M in 2025, growth of about 5.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 68% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B—
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-146.6%
Shareholder yield0.0%
Intrinsic value vs. price−28%

Growth and quality

Revenue growth (1 yr)-46.5%
Revenue growth (5 yrs, per year)5.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-390.7%
ROIC (5-yr avg.)-106.2%
Profitable years (of last 10)0
Years paying a dividend2

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$32M$30M$57M$47M$38M$31M$24M
Net income-$465M-$374M-$73M-$114M-$23M-$88M-$48M
Free cash flow-$18M$4M$19M-$21M-$21M-$29M-$31M
EPS (diluted)$-49.70$-36.48$-8.05$-16916.31$-2246.70$-8854.63$-4.76
Net margin-1469.8%-1236.4%-128.7%-244.6%-61.4%-282.4%-201.7%
ROIC————-106.2%—-188100.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Scilex Holding Co stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 28% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Scilex Holding Co pay a dividend?

Not currently.

Is Scilex Holding Co a good stock to buy?

We do not give buy or sell advice. Scilex Holding Co scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.